Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An evaluation of sotorasib for the treatment of patients with non-small cell lung cancer with KRASG12C mutations.

Expert opinion on pharmacotherapy - 1 Oct 2022

Strohbehn Garth W, Sankar Kamya, Qin Angel, Kalemkerian Gregory P

Abstract excerpt

INTRODUCTION: Improving the clinical outcomes of patients with KRASG12C-mutated non-small cell lung cancer (NSCLC), the majority of whom are current or former smokers, has been a barrier to improving population-level outcomes in NSCLC. Novel and effective KRASG12C inhibitors are emerging, and sotorasib is the first member of that class to achieve commercial availability. AREAS COVERED: In this review, we survey...

Topics

Join the communities discussing this publication.

Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Mutation
Proto-Oncogene Proteins p21(ras)

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 36217844
DOI: 10.1080/14656566.2022.2134777

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An evaluation of sotorasib for the treatment of patients with non-small cell lung cancer with KRASG12C mutations.PMID 36217844Read ↗

[Sotorasib in non-small cell lung cancer KRAS G12C-mutated: from evidence to clinical practice].Semantic proximity Read ↗

Sotorasib: a KRASG12C inhibitor for non-small cell lung cancer.Semantic proximity Read ↗

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.Semantic proximity Read ↗

Targeted Therapies for Previously "Undruggable" KRAS-Mutated Non-Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib.Semantic proximity Read ↗

Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer.Semantic proximity Read ↗

Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.Semantic proximity Read ↗

Sotorasib: First Approved KRAS Mutation Inhibitor for the Treatment of Non-small Cell Lung Cancer.Semantic proximity Read ↗

KRAS-targeted therapy in the treatment of non-small cell lung cancer.Semantic proximity Read ↗

Sotorasib for Lung Cancers with KRAS p.G12C Mutation.Semantic proximity Read ↗

On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma.Semantic proximity Read ↗

An updated overview of K-RAS G12C inhibitors in advanced stage non-small cell lung cancer.Semantic proximity Read ↗

Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.